Teva has launched a digitally-enabled inhaler in the UK, the first European market for the device, for use by patients with asthma and chronic obstructive pulmonary disorder (COPD). The GoResp ...

The Federal Trade Commission has opened an investigation into Teva Pharmaceuticals, citing the company’s refusal to take down ...

Teva loses US appeal to keep inhaler patents on FDA protected drug list December 20, 2024 Israel's Teva Pharmaceutical Industries and French drugmaker Sanofi said a study of a drug to treat ...

In February 2025, Teva Pharmaceuticals and Alvotech announced the U.S. launch of SELARSDI™ (ustekinumab-aekn), a biosimilar to Stelara® (ustekinumab), following FDA approval and a provisional ...

Teva Pharmaceutical Industries Limited develops ... UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic ...

Alvotech and Teva Pharmaceuticals announced the US Food and Drug Administration (FDA) has accepted for review a Biologics ...